Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
PDUFA Date: Replimune expects an FDA decision on RP1 for anti-PD-1 failed melanoma by July 22, 2025, with breakthrough therapy designation and priority review.
Launch Readiness: The company has completed commercial preparations, including a 60-person commercial team, distribution agreements, and manufacturing scale-up for rapid, broad launch.
Clinical Data: IGNYTE study shows about one-third of patients achieve durable responses with RP1, with median response duration over 20 months and over 55% alive at 3 years.
Financial Position: Ended March 31, 2025 with $483.8 million in cash, enough to fund operations into Q4 2026, covering commercial launch and pipeline development.
Pipeline Progress: Confirmatory Phase III IGNYTE-3 trial for RP1 is enrolling well, with over 100 global sites planned, and additional development ongoing for RP2 and RP3.
Cost Profile: In-house manufacturing gives RP1 an attractive cost of goods and ensures inventory for both launch and long-term supply needs.
Regulatory Interactions: No obstacles identified from FDA inspections or communications; company is confident in a broad RP1 label upon approval.
